Market Insights
Hypertension is the most commonly observed chronic disease, which causes elevations in systolic and diastolic blood pressure, which, in the long term, is a high-risk factor for coronary artery disease, heart failure, stroke, etc. Antihypertensive drugs are used to control blood pressure. The prevalence of chronic disease, a growing population, changing lifestyles, increased awareness of treatment options, new drug approvals, and healthcare expenditure are the major drivers of the antihypertensive drugs market.
The report titled “Global Anti-Hypertensive Drugs Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2023” offers strategic insights into the overall antihypertensive drugs market, along with the market size and estimates for the duration of 2016 to 2023. The research study in question provides an in-depth examination of multiple market segments based on drug class and geographical region. The drug class type segment studied for analyzing the overall antihypertensive drugs market is majorly segmented into diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators.
In order to help strategic decision-makers, the report also includes sections on competitive profiling of the leading players in the antihypertensive drugs market, pipeline analysis, attractive investment propositions, and market positioning of key manufacturers.
Geographically, the global market for antihypertensive drugs is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2013–2023. Market growth rates for the forecast period 2016–2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global antihypertensive drugs market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global antihypertensive drugs market.
This report concludes with a company profiles section that highlights major information about the key players engaged in the global antihypertensive drugs market. In-depth competitive environment analysis and historical years (2013 and 2014) of market size data are also provided in the report.Thus, the research study provides a holistic view of the global antihypertensive drug market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.
Based on the type of drug class, the global antihypertensive drugs market is segmented as follows:
- Diuretics
- ACE inhibitors
- ARBs
- Calcium channel blockers
- Beta-adrenergic blocker
- Alpha-adrenergic blocker
- Central Sympatholyics
- Renin-inhibitors
- Vasodilators
The global antihypertensive drugs market is segmented by drug class into different categories, such as diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, vasodilators. The ACE inhibitors control blood pressure by widening the blood vessels, which improves the flow of blood through the heart.
The ACE inhibitor dominates the market share of the antihypertensive drugs market in terms of value due to its mechanism of action, preference in the geriatric population, and cost. In the antihypertensive drug market, beta blockers are preferred by physicians to reduce blood pressure and the risk of complication, which is generally associated with chronic hypertension, while also having minimal side effects.
Diuretics are the next most commonly used antihypertensive drug on the market, as they are widely available and less expensive compared to others. Diuretics help maintain blood pressure by getting rid of sodium and water. Diuretics are conventionally used as the first line of treatment, though the trend is changing with new drug entrants’ approval and different mechanisms of action, which are further preferred by physicians depending on the suitability of the patient’s medical history. Due to this, ACE, beta-blockers, CCBs, ARBs, etc., are used nowadays and exist in the market according to patient needs.
For the purpose of this study, the global antihypertensive drugs market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The global market for antihypertensive drugs is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East. The global antihypertensive drug market is dominated by the North American region, which occupies the major market. The major contributor in this region is the US due to factors such as the prevalence of hypertension, the rise in the geriatric population, the upcoming new drug in the pipeline, and the use of combination therapy.
Europe is the next market up, with the United Kingdom, Germany, France, Italy, and Spain leading the way. According to research studies, as Europe’s population has grown, so has the number of people suffering from hypertension; thus, addressing the unmet need for appropriate healthcare planning and expenditure is one of the major driving factors for the European market.
The Asia-Pacific region is the most lucrative market, with major contributors being Japan, India, and China. Asia-Pacific carries almost half of the world’s cardiovascular burden, in which up to 66% of subtypes of CVD contribute to hypertension due to increases in urbanization and the adoption of unhealthy lifestyles and foods. Thus, developed countries dominate the market for hypertensive patients, while emerging economies with a growing population and increasing government spending on health care offer a lucrative alternative.
